Trident Lifeline Ltd
Incorporated in 2014, Trident Lifeline Ltd manufactures and sells pharmaceuticals
products[1]
- Market Cap ₹ 316 Cr.
- Current Price ₹ 275
- High / Low ₹ 339 / 222
- Stock P/E 22.2
- Book Value ₹ 57.2
- Dividend Yield 0.00 %
- ROCE 27.4 %
- ROE 22.0 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Company has delivered good profit growth of 78.5% CAGR over last 5 years
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|
| 5 | 10 | 22 | 32 | 45 | 68 | 72 | |
| 5 | 8 | 19 | 25 | 36 | 50 | 53 | |
| Operating Profit | -0 | 1 | 3 | 6 | 9 | 18 | 19 |
| OPM % | -5% | 13% | 12% | 20% | 20% | 26% | 27% |
| 0 | 0 | 1 | 1 | 2 | 3 | 3 | |
| Interest | 1 | 0 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 2 | 2 |
| Profit before tax | -1 | 1 | 3 | 7 | 10 | 18 | 19 |
| Tax % | -26% | 26% | -32% | 9% | 28% | 27% | |
| -1 | 1 | 4 | 6 | 7 | 13 | 14 | |
| EPS in Rs | -2.58 | 1.26 | 4.94 | 5.23 | 6.12 | 11.35 | 12.39 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 69% |
| 3 Years: | 46% |
| TTM: | 42% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 78% |
| 3 Years: | 49% |
| TTM: | 72% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -7% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 20% |
| Last Year: | 22% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 3 | 5 | 8 | 12 | 12 | 12 |
| Reserves | -6 | -5 | -3 | 34 | 41 | 54 |
| 6 | 5 | 2 | 3 | 6 | 15 | |
| 3 | 7 | 7 | 7 | 14 | 17 | |
| Total Liabilities | 6 | 11 | 14 | 56 | 73 | 98 |
| 1 | 1 | 1 | 3 | 8 | 15 | |
| CWIP | 0 | 0 | 0 | 0 | 4 | 1 |
| Investments | 0 | 0 | 0 | 4 | 4 | 12 |
| 6 | 10 | 12 | 49 | 57 | 70 | |
| Total Assets | 6 | 11 | 14 | 56 | 73 | 98 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| -1 | 1 | -0 | -17 | 1 | -3 | |
| -0 | -1 | -0 | -6 | -11 | -8 | |
| 1 | -1 | 1 | 36 | 2 | 7 | |
| Net Cash Flow | 0 | -0 | 0 | 14 | -8 | -4 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 97 | 24 | 83 | 140 | 112 | 110 |
| Inventory Days | 104 | 349 | 95 | 129 | 137 | 167 |
| Days Payable | 202 | 266 | 134 | 87 | 94 | 97 |
| Cash Conversion Cycle | -1 | 107 | 44 | 183 | 155 | 180 |
| Working Capital Days | -12 | 12 | 49 | 274 | 246 | 226 |
| ROCE % | 34% | 55% | 25% | 19% | 27% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Investor Presentation
30 Jul - Earnings Presentation for the quarter ended 30th June, 2025 (Q1FY26).
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
30 Jul - Copies of newspaper advertisement published on July 30, 2025 regarding extract of the Un-audited Standalone and Consolidated Financial Statements for the quarter ended June 30, …
-
Statement Of Deviation For The Quarter Ended June 30,2025
28 Jul - No deviation in utilization of Rs. 35.34 Cr IPO funds as of June 30, 2025, certified by auditor.
-
Appointment Of Secretarial Auditor Of The Company For The First Term From Financial Year 2025-26 To FY 2029-30 Subject To Approval Of The Members In Ensuing AGM
28 Jul - Q1 FY25-26 unaudited results approved; secretarial auditor appointed for five years, subject to shareholder approval.
- Financial Result For The Quarter Ended June 2025 28 Jul
Business Overview:[1]
TFL is a pharmaceutical Company with business operations spanning formulations under its own brands, loan licence model and contract manufacturing model.
a) Pharmaceutical formulations export:
Company has a presence in 40 countries, including African, Latin America, and East
Asian countries, with ~945 registered export market products, and ~2016 export market products are under registration
b) Contract manufacturing:
Company follows an Asset-light third-party contract manufacturing model thus entailing limited direct investment in manufacturing capacities